New Alzheimer's drug aims to boost memory in Early-Stage patients
Symptom relief
Recruiting now
This study tests a new drug called NSC001 in 90 people with mild to moderate Alzheimer's disease. The main goal is to see if the drug is safe and tolerable, and to explore whether it can improve thinking and memory. Participants will be randomly assigned to receive either NSC001 …
Phase: PHASE1, PHASE2 • Sponsor: NSC-Therapeutics • Aim: Symptom relief
Last updated May 13, 2026 15:59 UTC